(Q34182312)

31 July 2017

1 reference

title

Miglitol, a new alpha-glucosidase inhibitor (English)

1 reference

31 July 2017

Sels JP

1

1 reference

31 July 2017

Huijberts MS

series ordinal

2

1 reference

31 July 2017

Wolffenbuttel BH

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

1

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

149-156

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.149

Effects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral- and acid alpha-glucosidases in human fibroblasts and HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.149

alpha-Glucosidase inhibition by miglitol in NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.149

The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.149

Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.149

Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.149

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.149

Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.149

Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.149

Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.149

Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.149

21 January 2018

Identifiers

DOI

10.1517/14656566.1.1.149

1 reference

31 July 2017

1 reference